Tekla Healthcare Investor... (HQH)

HQH offers high yields with a biotech and small/mid-cap tilt, but relies on capital payouts, making it less tax-efficient and more volatile. Active management and venture capital-style investing add a...

Healthcare CEFs are under pressure from regulatory shifts, but sector defensiveness and discounted valuations can create long-term opportunities. Within the CEF structure, we also have the added benef...

Groundbreaking AI-powered initiatives are set to transform the healthcare landscape, potentially revolutionizing cancer research and healthcare investing. Aberdeen Investments' four healthcare-focused...

I maintain my buy rating on HQH for its high 13.6% yield, strong dividend coverage, and efficient healthcare sector diversification. HQH trades at an 8% discount to NAV, offering an attractive entry p...

HQH offers a compelling mix of high yield and growth exposure to healthcare, trading at a discount to NAV with recent outperformance versus benchmarks. The fund benefits from strong healthcare industr...